Shanghai Pharmaceuticals (601607) Q1 2025 earnings summary

Executive summary

• Achieved revenue of RMB 70.76 billion in Q1 2025, up 0.87% year-over-year.

• Net profit attributable to shareholders was RMB 1.33 billion, down 13.56% year-over-year.

• R&D investment reached RMB 612 million, with steady progress in innovative drug pipelines.

• Industrial and commercial segments contributed RMB 5.32 billion and RMB 8.34 billion in profit, respectively.

Financial highlights

• Operating income: RMB 70.76 billion, up 0.87% year-over-year.

• Net profit attributable to shareholders: RMB 1.33 billion, down 13.56% year-over-year.

• Basic and diluted EPS: RMB 0.36, down 14.29% year-over-year.

• Operating cash flow improved to -RMB 2.20 billion from -RMB 5.47 billion year-over-year.

• Total assets at period end: RMB 225.87 billion, up 2.11% from year-end 2024.

Outlook and guidance

• Continued focus on R&D innovation and new product launches.

• Expansion of innovative business models and strategic partnerships in commercial segment.